Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr Fürstenau on Safety Data From the GAIA/CLL13 Trial in Untreated CLL

July 25th 2024

Moritz Fürstenau, MD, discusses the safety of venetoclax plus obinutuzumab with/without ibrutinib in fit patients with chronic lymphocytic leukemia.

Time-Limited Acalabrutinib/Obinutuzumab Produces Durable Responses in Treatment-Naive CLL

July 25th 2024

Time-limited acalabrutinib plus obinutuzumab produced responses in treatment-naive chronic lymphocytic leukemia.

Patient with R/R CLL Treated with 2L Venetoclax Therapy

July 23rd 2024

A hematology and oncology specialist presents the case of a 66-year-old man with chronic lymphocytic leukemia.

Expert Insights for Long-Term Treatment Planning in CLL

July 23rd 2024

Catherine C. Coombs, MD, outlines considerations for long-term treatment planning, particularly in younger patients with chronic lymphocytic leukemia.

Dr Fürstenau on the Rationale for the GAIA/CLL13 Trial in Previously Untreated CLL

July 23rd 2024

Moritz Fürstenau, MD, discusses the rationale for launching the phase 3 GAIA/CLL13 in previously untreated, fit patients with chronic lymphocytic leukemia.

Pembrolizumab Plus B-Cell Receptor Inhibitors Generates Responses in Richter Transformation of CLL/SLL

July 22nd 2024

Pembrolizumab plus ibrutinib or idelalisib produced responses in patients with Richter transformation of chronic lymphocytic leukemia.

Dr Shadman on the Evaluation of Zanbrutinib Plus Sonrotoclax in Treatment-Naive CLL

July 22nd 2024

Mazyar Shadman, MD, MPH, discusses the rationale for combining sonrotoclax plus zanubrutinib for treatment-naive chronic lymphocytic leukemia.

Navigating Treatment Approaches for R/R CLL

July 22nd 2024

A clinician outlines their treatment strategy for relapsed/refractory chronic lymphocytic leukemia patients, emphasizing how previous treatment history influences subsequent therapy choices.

EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches

July 22nd 2024

An expert in the field provides insights into current clinical trials investigating the efficacy of combined BCL-2 inhibitor and BTK inhibitor therapies.

Fixed-Duration Venetoclax-Based Combos Maintain Benefit in Frontline CLL

July 17th 2024

Moritz Fürstenau, MD, discusses 4-year follow-up findings from the phase 3 GAIA/CLL13 trial in patients with CLL.

Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL

July 16th 2024

John N. Allan, MD, provides clinical insights on how appropriate dose ramp-up practices for venetoclax can minimize adverse events and optimize patient outcomes.

Perspectives on Shared Decision-Making in the Treatment of CLL

July 16th 2024

Bita Fakhri, MD, MPH, discusses the importance of patient involvement in the shared decision-making process to individualize treatment and improve outcomes.

Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL

July 15th 2024

Experts analyze the potential applications of triplet therapy (venetoclax, BTK inhibitor, and obinutuzumab) in first-line chronic lymphocytic leukemia treatment, focusing on patient subgroups most likely to benefit from this approach.

Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D

July 15th 2024

Preliminary results for treatment with zanubrutinib + venetoclax in patients with high-risk TN CLL/SLL with del(17p) and/or TP53 mutation showed Promising efficacy in a high-risk population with deep and durable responses according to data from arm D of the phase 3 SEQUOIA trial (NCT03336333).

Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy

July 15th 2024

A chronic lymphocytic leukemia expert examines patient criteria for first-line doublet therapy (venetoclax plus BTK inhibitor) versus triplet therapy, while also addressing findings from the CAPTIVATE trial.

Dr Phillips on Evolving Treatment Strategies in Both MCL and CLL

July 11th 2024

Tycel Phillips, MD, discusses the evolution of treatment strategies for patients with either chronic lymphocytic leukemia or mantle cell lymphoma.

Dr Fürstenau on the Efficacy of Frontline Venetoclax-Based Combinations in CLL

July 10th 2024

Moritz Fürstenau MD, discusses 4-year follow-up findings from the phase 3 GAIA/CLL13 trial in patients with CLL.

Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL

July 9th 2024

Experts on chronic lymphocytic leukemia detail how clinical trial data on doublet therapies help inform treatment decisions in the first line.

Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL

July 9th 2024

Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.

Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib

July 8th 2024

The panelists explore strategies for managing front-line chronic lymphocytic leukemia (CLL) treatment in patients with pre-existing hypertension and atrial fibrillation.